Investment Thesis
Alkermes faces existential financial distress with persistent unprofitability (net loss $66.5M), operating cash burn of $165.7M, and declining revenue (-5.2% YoY), indicating fundamental product-market deterioration. At current burn rates, the company has approximately 2 years of cash runway before liquidity crisis, and negative interest coverage (-4.0x) makes debt servicing increasingly precarious.
Strengths
- Adequate liquidity buffer with $351.6M cash reserves and 2.27x current ratio providing short-term operational flexibility
- Moderate leverage at 0.87x debt-to-equity ratio reduces immediate refinancing pressure
- Substantial $4.3B asset base suggests valuable pharmaceutical intellectual property and production capacity
Risks
- Catastrophic cash burn of $165.7M annual operating cash flow with negative $169.8M free cash flow implying ~2-year solvency window
- Consistent unprofitability across all dimensions (net margin -16.9%, operating margin -12.3%, ROE -3.8%) demonstrating systemic business model failure
- Negative interest coverage ratio (-4.0x) indicates inability to service debt from operations; revenue decline (-5.2% YoY) suggests deteriorating competitive position in pharmaceutical market
Key Metrics to Watch
- Path to operating cash flow positive inflection and quarterly burn rate trends
- Revenue stabilization and product portfolio performance metrics
- Cash balance trajectory and strategic alternatives (partnership, acquisition, restructuring)
- Operating margin improvement and cost structure adjustments
Financial Metrics
Revenue
392.9M
Net Income
-66.5M
EPS (Diluted)
$-0.40
Free Cash Flow
-169.8M
Total Assets
4.3B
Cash
351.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-12.3%
Net Margin
-16.9%
ROE
-3.8%
ROA
-1.6%
FCF Margin
-43.2%
Balance Sheet & Liquidity
Current Ratio
2.27x
Quick Ratio
1.70x
Debt/Equity
0.87x
Debt/Assets
58.9%
Interest Coverage
-4.05x
Long-term Debt
1.5B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T07:55:32.610258 |
Data as of: 2026-03-31 |
Powered by Claude AI